Human Insulin from Recombinant DNA Technology-Reference-Cited by-同舟云学术

Human Insulin from Recombinant DNA Technology

Published:1983-02-11 Issue:4585 Volume:219 Page:632-637
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Johnson Irving S.¹

Affiliation:

1. Lilly Research Laboratories, a division of Eli Lilly and Company, Indianapolis, Indiana 46285.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference19 articles.

1. Bulletin of the Atomic Scientists 33: 22 (1977).

2. Livestock and Slaughter Reports 1980

3. National Institutes of Health Publ. 78-1588: 9 (1978).

4. U.S. patent number 4 237 224.

5. BAKER, R.S., PRELIMINARY STUDIES ON THE IMMUNOGENICITY AND AMOUNT OF ESCHERICHIA-COLI POLYPEPTIDES IN BIOSYNTHETIC HUMAN INSULIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY, LANCET 2: 1139 (1981).

Cited by 305 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Escherichia coli in the production of biopharmaceuticals;Biotechnology and Applied Biochemistry;2024-09-08

2. Diabetes Management in Transition: Market Insights and Technological Advancements in CGM and Insulin Delivery;Advanced Sensor Research;2024-07-11

3. Escherichia coli as a versatile cell factory: Advances and challenges in recombinant protein production;Protein Expression and Purification;2024-07

4. Solid Lipid Nanoparticles: a promising drug delivery system and their potential for peptide and protein therapeutics;Dosage Forms - Emerging Trends and Prospective Drug-Delivery Systems [Working Title];2024-05-31

5. Integrating MLSecOps in the Biotechnology Industry 5.0;The Role of Cybersecurity in the Industry 5.0 Era [Working Title];2024-05-10